close 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

DTE

31.57

-0.63%↓

IBE

19.06

-0.47%↓

RWE

55

-2.34%↓

ELE

34.28

-1.01%↓

FORTUM.FI

20.53

-5.7%↓

DTE

31.57

-0.63%↓

IBE

19.06

-0.47%↓

RWE

55

-2.34%↓

ELE

34.28

-1.01%↓

FORTUM.FI

20.53

-5.7%↓

DTE

31.57

-0.63%↓

IBE

19.06

-0.47%↓

RWE

55

-2.34%↓

ELE

34.28

-1.01%↓

FORTUM.FI

20.53

-5.7%↓

DTE

31.57

-0.63%↓

IBE

19.06

-0.47%↓

RWE

55

-2.34%↓

ELE

34.28

-1.01%↓

FORTUM.FI

20.53

-5.7%↓

DTE

31.57

-0.63%↓

IBE

19.06

-0.47%↓

RWE

55

-2.34%↓

ELE

34.28

-1.01%↓

FORTUM.FI

20.53

-5.7%↓

Home・Aandelen Lijst・Voltalia SA
Search

Voltalia SA

Gesloten

SectorNutsvoorzieningen

6.86 2.08

Buy

Prijsupdate 23 mrt 2026, 16:29 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

6.28

Max

7.05

Belangrijke statistieken

By Trading Economics

Inkomsten

-28M

-68M

Verkoop

74M

331M

Winstmarge

-20.659

Werknemers

2,006

EBITDA

-543K

66M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+34.73% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-39M

855M

Vorige openingsprijs

4.78

Vorige sluitingsprijs

6.86

Nieuwssentiment

By Acuity

29%

71%

19 / 90 Rangschikking in Utilities

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

7.472 / 7.611 Steun & Weerstand

Voltalia SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

DJ

Lezen

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

DJ

Lezen

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

DJ

Lezen

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

DJ

Lezen

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

DJ

Lezen

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

DJ

Lezen

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

DJ

Lezen

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

DJ

Lezen

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

DJ

Lezen

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

DJ

Lezen

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

DJ

Lezen

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

DJ

Lezen

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

DJ

Lezen

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

DJ

Lezen

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

DJ

Lezen

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

DJ

Lezen

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

DJ

Lezen

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

DJ

Lezen

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

DJ

Lezen

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

DJ

Lezen

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

DJ

Lezen

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

DJ

Lezen

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

DJ

Lezen

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

DJ

Lezen

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 20:50 UTC

Marktinformatie
Winsten
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Voltalia SA Prognose

Koersdoel

By TipRanks

34.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9 EUR  34.73%

Hoogste 9 EUR

Laagste 9 EUR

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Voltalia SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Voltalia SA - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

7.472 / 7.611Steun & Weerstand

Korte Termijn

Bullish Evidence

Bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Lange Termijn

Weak Bearish Evidence

There is one bearish event.

Sentiment

By Acuity

19 / 90 Rangschikking in Nutsvoorzieningen

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

DTE

Deutsche Telekom AG

31.57

↓-0.63%

IBE

Iberdrola SA

19.06

↓-0.47%

RWE

RWE AG

55

↓-2.34%

ELE

Endesa SA

34.28

↓-1.01%

FORTUM.FI

Fortum Oyj

20.53

↓-5.7%
help-icon Live chat